Using Bimatoprost eye drops to treat Graves' Orbitopathy
Official title: The Role of Bimatoprost in Graves' Periorbitopathy
Run by Johns Hopkins University · NCT03708627 · Data updated 2026-11-12
This study is testing if Bimatoprost eye drops can help reduce bulging eyes and other symptoms in people with Graves' disease.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3 (estimated) |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Status | Recruiting |
| Started | November 1, 2017 |
| Main results expected | July 1, 2029 |
| Study ends | July 1, 2031 |
| Registry record updated | July 16, 2026 |
| Trial ID | NCT03708627 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with Graves' Ophthalmopathy who exhibit exophthalmos or proptosis.
✕Probably not a fit
Patients who are currently pregnant, taking steroids, or have active Graves' disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of Bimatoprost, a topical eye drop typically prescribed for glaucoma, to induce fat atrophy around the eyes in patients suffering from Graves' disease. The study aims to assess the effectiveness of this treatment in reducing symptoms associated with Graves' Ophthalmopathy, particularly exophthalmos or proptosis. Participants will receive Bimatoprost ophthalmic solution and will be monitored for changes in their condition throughout the trial.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with Graves' Orbitopathy, potentially improving their quality of life.
How similar studies have gone: While the use of Bimatoprost for this specific condition is novel, similar approaches using topical treatments for ocular conditions have shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis - Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids \-
Where it's running
-
University of Washington
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Emily Li, MD — Johns Hopkins University
- Study coordinator: Emily Li, MD
- Email: eli20@jhmi.edu
- Phone: 410-955-1112
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
AI-based MRI and ultrasound for thyroid-related eye disease
This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.
-
Tofacitinib for steroid‑resistant moderate-to-severe thyroid eye disease
This will test whether taking oral tofacitinib (5 mg twice daily) for 24 weeks can reduce eye bulging and inflammation in adults with moderate-to-severe thyroid eye disease who don't respond to or cannot take high-dose steroids.
-
Links between inflammation, thyroid antibodies, and retinal changes in Graves disease
This study will see if blood markers of inflammation and thyroid antibodies are linked to retinal measurements from OCT in adults with Graves disease and in healthy adults.
-
Atorvastatin and vitamin D for active thyroid eye disease
This trial tests whether taking atorvastatin and/or vitamin D with usual care can reduce eye inflammation and bulging in adults with active thyroid eye disease.
-
Teprotumumab for treating thyroid eye disease and thyroid dysfunction
This study is testing how well teprotumumab can help people with thyroid eye disease who have serious symptoms like bulging eyes, pain, and double vision.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.